| Biologic Therapy |
0 |
0.98 |
| Vascular Anomaly |
0 |
0.99 |
| Breast Cancer |
0 |
0.65 |
| Antiretroviral Therapy for HIV Infection |
0 |
0.57 |
| Genomic Medicine |
0 |
0.51 |
| Nucleoside Reverse Transcriptase Inhibitors |
0 |
0.31 |
| Patient Safety |
0 |
0.29 |
| mTOR Inhibitor |
0 |
0.26 |
| Child |
0 |
0.25 |
| Angiogenesis Inhibitors |
0 |
0.24 |
| Hemangioma |
0 |
0.19 |
| Hospital |
0 |
0.19 |
| Pediatric Dermatology |
0 |
0.18 |
| Targeted Cancer Therapy |
0 |
1 |
| Biomarker |
0 |
0.13 |
| Clinical Research |
0 |
0.13 |
| Wound Management |
0 |
0.12 |
| Osler-Weber-Rendu Syndrome |
0 |
0.09 |
| Adverse Effects |
0 |
0.06 |
| Arteriovenous Malformation |
0 |
0.06 |
| Beta Blockers |
0 |
0.06 |
| Breast |
0 |
0.06 |
| Cancer |
0 |
0.06 |
| Failure to Thrive |
0 |
0.06 |
| Food and Drug Administration (FDA) |
0 |
0.06 |
| Humanized Monoclonal Antibody |
0 |
0.06 |
| Jobs |
0 |
0.06 |
| Neurofibromatosis |
0 |
0.06 |
| Pericardial Effusion |
0 |
0.06 |
| Proteus Syndrome |
0 |
0.06 |
| Quality of Life |
0 |
0.06 |
| Retroperitoneum |
0 |
0.06 |
| Somatic |
0 |
0.06 |
| Surgery |
0 |
0.06 |
| Telangiectasia |
0 |
0.06 |
| Tissue |
0 |
0.06 |
| Tuberous Sclerosis |
0 |
0.06 |
| Tumor |
0 |
0.06 |
| Wound |
0 |
0.06 |